Gökhan İNANGİL, Murat KUYUMCU, Hüseyin ŞEN, Sezai ÖZKAN, Güner DAĞLI

Cerrahide bir birincil koruyucu hekimlik uygulaması: İntraoperatif böbrek hasarının önlenmesi

Cerrahi sonrası oluşan akut böbrek yetmezliği, yüksek morbidite ve mortaliteye sahip ciddi bir komplikasyondur. Cerrahi girişim uygulanan hastalarda, en ideali postoperatif devrede oluşan komplikasyonlarla uğraşmaktan ziyade, akut böbrek hasarı (ABH) gelişiminin önlenmesidir. Başarılı bir önlem; risk grubundaki hastaları belirlemek ve optimize etmek, uygun anestezik plan yapmak, renal fonksiyonun takibinde uygun ve spesifik monitorizasyon yöntemlerini uygulamak ve renal fonksiyonlarda bozulma başladığında gerekli etkin yöntemleri uygulamaktır. Bu yazıda, ABH nedenleri ve risk faktörleri, ABH insidansı ve koruyucu hekimlik uygulamaları ile ABH oluşumunu önlemeye yönelik koruyucu hekimlik yöntemlerini gözden geçirdik.

[A primary preventive medicine implemantation: Prevention of intraoperative kidney damage]

Post surgical acute renal failure (ARF) is a serious complication with high morbidity and mortality. The prevention of the development of ARF must be preferable approach rather than dealing with the complications for the patients undergoing surgery. Identifying and optimizing the patients in the risk group, making out an appropriate anesthetic plan, implementing specific monitoring and appropriate methods for following up the renal function and implementing effective methods when distortion comes out in renal function are basic principles for a successful prevention. In this article, we reviewed that, the causes and risk factors about ARF, incidence of ARF and preventive medicine methods to prevent ARF.

PDF

___

1 Kolh P. The burden of renal failure after cardiac surgery. Eur J Cardiothorac Surg. 2011; 40: 708-709.
2 Heyman SN, Fuchs S, Brezis M. The role of medullary ischemia in acute renal failure. N Horizons. 1995; 3: 597-607.
3 Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care. 2004; 8: 204-212.
4 Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Critical Care. 2007; 1(11): 31.
5 Moran SM, Myers BD. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int. 1985; 27: 928-937.
6 Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury. Pediatric Nephrology. 2008; 23: 215-217.
7 Schmitt-Ott KM, Mori K, Li JY, et al: Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007; 18: 407-413.
8 Westhuyzen J, Cystatin C. A promising marker and predictor of impaired renal function. Ann Clin Lab Sci. 2006; 36: 387-394.
9 Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002; 40: 221-226.
10 Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003; 18: 2024-2031.
11 Herget-Rosenthal S, Pietruck F, Volbracht L, et al. Serum cystatin C – a superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin Nephrol. 2005; 64: 41-46.
12 Rule AD, Bergstralh EJ, Slezak JM, et al. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int. 2006; 69: 399-405.
13 Manetti L, Pardini E, Genovesi M, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest. 2005; 28: 346-349.
14 Melnikov VY, Faubel S, Siegmund B, et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest. 2002; 110: 1083-1091.
15 Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006; 70: 199-203.
16 Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol. 2006; 290: F517-529.
17 Han WK, Bailly V, Abichandani R, et al. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002; 62: 237-244.
18 Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007; 18: 904- 912.
19 Novis BK, Roizen MF, Aronson S, Thisted RA. Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg. 1994; 78: 143-149.
20 Bove T, Calabro MG, Landoni G, et al. The incidence and risk of acute renal failure after cardiac surgery. J Cardiothorac Vasc Anesth. 2004; 18: 442-445.
21 Brienza N, Giglio MT, Marucci M. Preventing acute kidney injury after noncardiac surgery. Curr Opin Crit Care. 2010; 16: 353-358.
22 Carmichael P, Carmichael AR. Acute renal failure in the surgical setting. ANZ J Surg. 2003; 73: 144-153.
23 Kheterpal S, Tremper KK, Englesbe MJ, et al. Predictors of postoperative acute renal failure after non cardiac surgery in patients with previously normal renal function. Anesthesiology. 2007; 107: 892-902.
24 Kashyap VS, Cambria RP, Davison JK, L’Italien GJ. Renal failure after thoracoabdominal aortic surgery. J Vasc Surg. 1997; 26: 949-957.
25 Cabezuelo JB, Ramirez P, Rios A, et al. Risk factors of acute renal failure after liver transplantation. Kidney Int. 2006; 69: 1073- 1080.
26 Sear JW. Kidney dysfunction in the postoperative period. Br J Anaesth. 2005; 95: 20-32.
27 Agarwal RC, Jain RK, Yadava A. Prevention of perioperative renal failure. Indian J Anaesth. 2008; 52: 38-43.
28 Tang I, Murray PT. Prevention of perioperative acute renal failure: what works? Best Prac Res Clin Anaesth. 2004; 18: 91-111.
29 Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998; 128: 194-203.
30 Solomon R, Werner C, Mann D, D’Elia J, Silva P. Effects of saline, mannitol and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994; 331: 1416-1420.
31 Brandstrup B, Svensen C, Engquist A. Hemorrhage and operation cause a contraction of the extracellular space needing replacement: evidence and implications? A systematic review. Surgery. 2006; 139: 419-432.
32 Foulds RA. Clinical development of dopexamine hydrochloride (Dopacard) and an overview of its hemodynamic effects. Am J Cardiol. 1988; 62: 41c–45c.
33 Gamulin Z, Forster A, Morel D, et al. Effects of infra-renal aortic cross-clamping on renal hemodynamics in humans. Anesthesiology. 1984; 61: 394-399.
34 Garwood S, Swamidoss CP, Davis EA, Samson L, Hines RL. A case series of low-dose fenoldopam in seventy cardiac surgical patients at increased risk of renal dysfunction. J Cardiothorac Vasc Anesth. 2003; 17: 17-21.
35 Chappell D, Jacob M, Hofmann-Kiefer K, et al. A rational approach to perioperative fluid management. Anesthesiology. 2008; 109: 723- 740.
36 Shoemaker WC, Appel PL, Kram HB. Haemodynamic and oxygen transport responses in survivors and nonsurvivors of high-risk surgery. Crit Care Med. 1993; 21: 977- 990.
37 Brienza N, Giglio MT, Marucci M, Fiore T. Does perioperative hemodynamic optimization protect renal function in surgical patients? A metaanalytic study. Crit Care Med. 2009; 37: 2079- 2090.
38 Boldt J, Brosch C, Rohm K, et al. Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac surgery patients. Br J Anaesth. 2008; 100: 457- 464.
39 Mahmood A, Gosling P, Vohra RK. Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery. Br J Surg. 2007; 94: 427-433.
40 O’Malley CM, Frumento RJ, Hardy MA, et al. A randomized, double-blind comparison of lactated Ringer’s solution and 0,9% NaCl during renal transplantation. Anesth Analg. 2005; 100: 1518-1524.
41 Vincent JL, Gerlach H. Fluid resuscitation in severe sepsis and septic shock: an evidencebased review. Crit Care Med. 2004; 32(11): S451-454.
42 Haase M, Haase-Fielitz A, Bellomo R, et al. Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med. 2009; 37: 39-47.
43 Better OS, Rubinstein I, Winaver JM, Knochel JP. Mannitol therapy revisited (1940–1997). Kidney Int. 1997; 52: 886-894.
44 Luke RG, Briggs JD, Allison ME, Kennedy AC. Factors determining response to mannitol in acute renal failure. Am J Med Sci. 1970; 259: 168-174.
45 Poullis M. Mannitol and cardiac surgery. Thorac Cardiovasc Surg. 1999; 47: 58-62.
46 Dorman HR, Sondheimer JH, Cadnapaphornchai P. Mannitol-induced acute renal failure. Medicine(Baltimore). 1990; 69:153- 159.
47 Seri I, Kone BC, Gullans SR, et al. Locally formed dopamine inhibits Na+-K+-ATPase activity in rat renal cortical tubule cells. Am J Physiol. 1988; 255: F666-673.
48 Weldon BC, Monk TG. The patient at risk for acute renal failure. Recognition, prevention, and preoperative optimization. Anesthesiol Clin North America. 2000; 18: 705-717.
49 Kellum JA. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001; 29: 1526-1531.
50 Perdue PW, Balser JR, Lipsett PA, Breslow MJ. ‘Renal dose’ dopamine in surgical patients: dogma or science? Ann Surg. 1998; 227: 470- 473.
51 Cantarovich F, Galli C, Benedetti L. High dose frusemide in established acute renal failure. Br Med J. 1973; 4: 449-455.
52 Lassnigg A, Donner E, Grubhofer G, et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol. 2000; 11: 97-104.
53 Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol. 1981; 15: 90-96.
54 Homsi E, Barreiro MF, Orlando JM, et al. Prophylaxis of acute renal failure in patients with rhabdomyolysis. Renal Fail. 1997; 19: 283-288.
55 Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit Care Resusc. 2007; 9: 60- 68.
56 Rodicio JL, Campo C, Ruilope LM. Renal effects of calcium antagonists. Nephrol Dial Transplant. 1995; 10(9): 17-22.
57 Morales JM, Andres A, Rodriguez Paternina E, et al. Calcium antagonist therapy prevents chronic cyclosporine nephrotoxicity after renal transplantation: a prospective study. Transplant Proc. 1992; 24: 89-91.
58 Antonucci F, Calo L, Rizzolo M, et al. Nifedipine can preserve renal function in patients undergoing aortic surgery with infrarenal crossclamping. Nephron. 1996; 74: 668-673.
59 Young EW, Diab A, Kirsh MM. Intravenous diltiazem and acute renal failure after cardiac operations. Ann Thorac Surg. 1998; 65: 1316- 1319.
60 Joob AW, Harman PK, Kaiser DL, Kron IL. The effect of reninangiotensin system blockade on visceral blood flow during and after thoracic aortic cross clamping. J Thorac Cardiovasc Surg. 1986; 91: 411-418.
61 Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol. 2003; 285: F167-177.
62 Rahman S, Kim G, Mathew A, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int. 1994; 45: 1731-1738.
63 Sward K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Critical Care Medicine. 2004; 32(6): 1310-1315.
64 Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. New England Journal of Medicine. 1997; 336: 828-834.
65 Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. American Journal of Kidney Diseases. 1998; 31: 674-680.
66 Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for preventing and treating acute kidney injury. Cochrane Database Syst Rev. 2009; 48(3): 285-293
67 Liu Y. Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am J Physiol. 1999; 277: F624-633.
68 Megyesi J, Andrade L, Vieira Jr JM, et al. Positive effect of the induction of p21WAF1/CIP1 on the course of ischemic acute renal failure. Kidney Int. 2001; 60: 2164-2172.
69 Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 1999; 55: 2423-2432.
70 Liu KD. Molecular mechanisms of recovery from acute renal failure. Crit Care Med. 2003; 31: S572-581.
71 Bonventre JV. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol. 2003; 14(1): S55-61.
72 Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: metaanalysis. Lancet. 2003; 362: 598-603.
73 Murphy MB, McCoy CE, Weber RR, et al. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. Circulation. 1987; 76: 1312-1318.
74 Landoni G, Biondi-Zoccai GG, Tumlin JA, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis. 2007; 49: 56-68.
75 Morelli A, Ricci Z, Bellomo R, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Crit Care Med. 2005; 33: 2451-2456.
76 Caimmi PP, Pagani L, Micalizzi E, et al. Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003; 17: 491-494.
77 Halpenny M, Rushe C, Breen P, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol. 2002; 19: 32-39.
78 Tumlin JA, Wang A, Murray P Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J. 2002; 143: 894-903.
79 Kini AS, Mitre CA, Kamran M, et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol. 2002; 89: 999-1002.
80 Halpenny M, Lakshmi S, O’Donnell A, et al. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia. 2001; 56: 953-960.
81 Julier K, da Silva R, Garcia C, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebocontrolled, multicenter study. Anesthesiology. 2003; 98: 1315-1327.
82 Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001; 345: 1359-1367.
83 Lecomte P, Van VB, Coddens J, et al. Tight perioperative glucose control is associated with a reduction in renal impairment and renal failure in nondiabetic cardiac surgical patients. Crit Care. 2008; 12: R154.
84 Jacob S, Nitschmann S. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360: 1283-1297.